Related Experiment Videos
'Photocisplatin' reagents.
Devanesan Loganathan1, Harry Morrison
1Department of Industrial and Physical Pharmacy, School of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907-2091, USA.
Current Opinion in Drug Discovery & Development
|July 19, 2005
Summary
Researchers are developing light-activated metal complexes, termed photocisplatin reagents, as novel cancer therapies. These compounds, like rhodium-based BISPHEN, offer targeted DNA damage upon UV/Vis light exposure, enhancing treatment specificity.
Area of Science:
- Medicinal Chemistry
- Photochemistry
- Oncology
Background:
- Cisplatin is a cornerstone of cancer chemotherapy, driving interest in alternative metal-based drugs.
- Photodynamic therapy's success highlights the potential of light-dependent treatment modalities.
- Phototherapy offers temporal and spatial specificity, desirable traits for drug development.
Purpose of the Study:
- To review recent advancements in photocisplatin reagents.
- To explore metal complexes that are thermally inert but light-activated for DNA interaction.
- To discuss the development of rhodium and related complexes as potential cancer therapeutics.
Main Methods:
- Literature review of photocisplatin reagents and their development.
- Analysis of light-activated metal complexes, specifically rhodium(III) complexes.
- Discussion of DNA-binding mechanisms upon photoactivation.
Main Results:
- Photocisplatin reagents, such as BISPHEN, are thermally inert complexes activated by UV/Vis light.
- These reagents form covalent bonds with DNA upon irradiation, mimicking cisplatin's action.
- Recent developments focus on elaborating these light-sensitive metal complexes.
Conclusions:
- Photocisplatin reagents represent a promising class of targeted cancer therapeutics.
- Light activation provides enhanced specificity compared to traditional chemotherapy.
- Further development of these metal complexes could lead to novel phototherapy strategies.